Real-World Clinical Effectiveness of Loncastuximab Tesirine Monotherapy for the Treatment of Relapsed/ Refractory Diffuse Large B-cell Lymphoma Following Chimeric Antigen T- Cell Therapy in the US

被引：0
|
作者：
Epperla, Narendranath [1 ]
Lucero, Melanie [2 ]
Bailey, Tom [3 ]
Mirams, Laura [3 ]
Cheung, Jolenta [3 ]
Amet, Mona [3 ]
Milligan, Gary [3 ]
Keir, Chris [4 ]
Chen, Lei [5 ]
机构：
[1] Ohio State Univ, Columbus, OH USA
[2] ADC Therapeut Amer Inc, New Providence, NJ USA
[3] Adelphi Real World, Macclesfield, Cheshire, England
[4] ADC Therapeut, Murray Hill, NJ USA
[5] ADC Therapeut, New Providence, NJ USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
loncastuximab tesirine; CD19-targeted chimeric antigen receptor T-cell therapy; real-world evidence; treatment sequencing;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ABCL-370
引用
收藏
页码：S476 / S476
页数：1
相关论文
共 50 条
  • [41] Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real-World Experience
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 9 - 10
  • [42] Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Spira, Alexander
    Zhou, Xiaolei
    Chen, Lei
    Gnanasakthy, Ari
    Wang, Luqiang
    Ungar, David
    Curiel, Rafael
    Liao, Laura
    Radford, John
    Kahl, Brad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (03): : 158 - 168
  • [43] Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma
    Chien, Hsu-Chih
    Morreall, Deborah
    Patil, Vikas
    Rasmussen, Kelli M.
    Li, Chungyang
    Yong, Christina M.
    Burningham, Zachary
    Masaquel, Anthony
    Halloran, Mary
    De Long-Sieg, Elisha
    Schulz, Mathias
    Sauer, Brian C.
    Halwani, Ahmad S.
    FUTURE ONCOLOGY, 2020, 17 (04) : 411 - 422
  • [44] In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine
    Caimi, Paolo F.
    Hamadani, Mehdi
    Carlo-Stella, Carmelo
    Nickaeen, Masoud
    Jordie, Eric
    Utsey, Kiersten
    Knab, Tim
    Zammarchi, Francesca
    Cucchi, Danilo
    Pantano, Serafino
    Havenith, Karin
    Wang, Ying
    Boni, Joseph
    EJHAEM, 2024, 5 (01): : 76 - 83
  • [45] Real-World Sequential Use of CD19-Directed Therapies for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab Preceding Chimeric Antigen Receptor T- Cell (CAR-T) Therapy
    Epperla, Narendranath
    Nastoupil, Loretta J.
    Feinberg, Bruce
    Pathak, Prathamesh
    Amoloja, Theresa
    Gentile, Danielle
    Saverno, Kim
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S477 - S477
  • [46] Long-Term Survival Projections of Loncastuximab Tesirine-Treated Patients in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Hamadani, Mehdi
    Graham, Christopher
    Liao, Laura
    Zhang, Kate
    Strat, Hannah
    Ungar, David
    Ai, Weiyun
    Chen, Lei
    Carlo-Stella, Carmelo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S373 - S373
  • [47] Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Kurtz, David M.
    Hogan, Gregory
    Schultz, Andre
    Chabon, Jacob J.
    Alizadeh, Ash A.
    Havenith, Karin
    Samari, Sara
    Kopotsha, Tim
    Wang, Luqiang
    Qin, Yajuan
    Wang, Ying
    Pantano, Serafino
    BLOOD, 2023, 142
  • [48] Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis
    Andrew Ip
    Alex Mutebi
    Tongsheng Wang
    Monika Jun
    Anupama Kalsekar
    Fernando Rivas Navarro
    Anthony Wang
    Rajesh Kamalakar
    Mariana Sacchi
    Brian Elliott
    Advances in Therapy, 2024, 41 : 1226 - 1244
  • [49] Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis
    Ip, Andrew
    Mutebi, Alex
    Wang, Tongsheng
    Jun, Monika
    Kalsekar, Anupama
    Navarro, Fernando Rivas
    Wang, Anthony
    Kamalakar, Rajesh
    Sacchi, Mariana
    Elliott, Brian
    ADVANCES IN THERAPY, 2024, 41 (03) : 1226 - 1244
  • [50] Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy.
    Fitzgerald, Lindsey
    Kittai, Adam
    Nastoupil, Loretta J.
    Waller, Alexandra
    Jacobson, Caron A.
    Saucier, Anna
    Kamdar, Manali K.
    Spradley, Janet
    Denlinger, Nathan
    Chipman, Jonathan
    Hu, Boyu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345